These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34889399)

  • 1. How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents.
    Driessen J; Tonino SH; Moskowitz AJ; Kersten MJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):240-246. PubMed ID: 34889399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
    Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing salvage therapy for Hodgkin lymphoma: progress and future challenges.
    Abeyakoon C; Kuruvilla J
    Expert Rev Hematol; 2024 Aug; 17(8):467-478. PubMed ID: 38916254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the best salvage therapy for Hodgkin lymphoma?
    Luttwak E; Moskowitz AJ
    Curr Opin Oncol; 2024 Sep; 36(5):346-352. PubMed ID: 39007229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease.
    Burton C; Allen P; Herrera AF
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433502. PubMed ID: 38728605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current Standards in the Treatment of Hodgkin Lymphoma].
    Hellmuth JC
    Dtsch Med Wochenschr; 2024 Jun; 149(12):702-708. PubMed ID: 38781993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.
    Randall MP; Spinner MA
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era.
    Varma G; Diefenbach C
    Semin Hematol; 2024 Aug; 61(4):253-262. PubMed ID: 39039012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
    Spinner MA; Sica RA; Tamaresis JS; Lu Y; Chang C; Lowsky R; Frank MJ; Johnston LJ; Miklos DB; Muffly LS; Negrin RS; Rezvani AR; Shiraz P; Shizuru JA; Weng WK; Binkley MS; Hoppe RT; Advani RH; Arai S
    Blood; 2023 Jun; 141(22):2727-2737. PubMed ID: 36857637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice.
    Benevolo Savelli C; Bisio M; Legato L; Fasano F; Santambrogio E; Nicolosi M; Morra D; Boccomini C; Freilone R; Botto B; Novo M
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
    Aoki T; Jiang A; Xu A; Yin Y; Gamboa A; Milne K; Takata K; Miyata-Takata T; Chung S; Rai S; Wu S; Warren M; Strong C; Goodyear T; Morris K; Chong LC; Hav M; Colombo AR; Telenius A; Boyle M; Ben-Neriah S; Power M; Gerrie AS; Weng AP; Karsan A; Roth A; Farinha P; Scott DW; Savage KJ; Nelson BH; Merchant A; Steidl C
    J Clin Oncol; 2024 Mar; 42(9):1077-1087. PubMed ID: 38113419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of paediatric refractory Hodgkin lymphoma with immunotherapy - A case report and literature review.
    Mogensen N; Cananau C; Ranta S; Karlén J; Kwiecinska A; Baecklund F
    Acta Paediatr; 2024 Jul; 113(7):1483-1495. PubMed ID: 38596833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing multi-source data for individualized care in Hodgkin Lymphoma.
    Parsons SK; Rodday AM; Upshaw JN; Scharman CD; Cui Z; Cao Y; Tiger YKR; Maurer MJ; Evens AM
    Blood Rev; 2024 May; 65():101170. PubMed ID: 38290895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects.
    Milrod CJ; Pelcovits A; Ollila TA
    Front Oncol; 2024; 14():1397053. PubMed ID: 38699638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making.
    Kahn JM; Mauz-Korholz C; Hernandez T; Milgrom SA; Castellino SM
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432420. PubMed ID: 38788179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival in cHL with novel agents.
    Merryman RW; LaCasce AS
    Blood; 2023 Jun; 141(22):2666-2668. PubMed ID: 37261856
    [No Abstract]   [Full Text] [Related]  

  • 17. [The guidelines for diagnosis and treatment of Hodgkin lymphoma in China (2022)].
    ; ;
    Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):705-715. PubMed ID: 36709163
    [No Abstract]   [Full Text] [Related]  

  • 18. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.
    Epperla N; Hamadani M
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):247-253. PubMed ID: 34889401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.
    Driessen J; de Wit F; Herrera AF; Zinzani PL; LaCasce AS; Cole PD; Moskowitz CH; García-Sanz R; Fuchs M; Müller H; Borchmann P; Santoro A; Schöder H; Zijlstra JM; Hutten BA; Moskowitz AJ; Kersten MJ
    Blood Adv; 2024 Jun; 8(11):2740-2752. PubMed ID: 38502227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma.
    Driessen J; Zwezerijnen GJC; Schöder H; Kersten MJ; Moskowitz AJ; Moskowitz CH; Eertink JJ; Heymans MW; Boellaard R; Zijlstra JM
    Blood Adv; 2023 Nov; 7(21):6732-6743. PubMed ID: 37722357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.